Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 17

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
 interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.ReclassificationsCertain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, net loss, or cash flows from operations.

2.REVENUE

The Company primarily generates revenue by performing molecular diagnostic testing. Revenue is recorded at the estimated transaction price. Control is transferred and revenue is recognized once test results are released to the healthcare provider and/or patient.

9

The following table presents details regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”):

Three months ended June 30,20252024(in millions)U.S.RoWTotalU.S.RoWTotalHereditary Cancer$84.6 $11.7 $96.3 $80.9 $10.6 $91.5 Tumor Profiling28.3 3.1 31.4 26.7 5.9 32.6 Prenatal47.5 0.1 47.6 44.2 0.2 44.4 Pharmacogenomics37.8 — 37.8 43.0 — 43.0 Total revenue$198.2 $14.9 $213.1 $194.8 $16.7 $211.5 

Six months ended June 30,20252024(in millions)U.S.RoWTotalU.S.RoWTotalHereditary Cancer$160.0 $22.6 $182.6 $157.2 $22.4 $179.6 Tumor Profiling54.3 6.4 60.7 50.6 12.9 63.5 Prenatal96.7 0.2 96.9 88.3 0.4 88.7 Pharmacogenomics68.8 — 68.8 81.9 — 81.9 Total revenue$379.8